EU accepts marketing application for Paratek’s antibiotic
European regulators have accepted an application from Paratek Pharmaceuticals seeking approval of the broad-spectrum antibiotic omadacycline for two types of infection.
Read More
Tag: ABSSSI
Motif Bio’s antibiotic granted US priority review
US regulators have accepted for review a targeted, Gram-positive investigational antibiotic developed by UK biopharma Motif Bio for the treatment of acute bacterial skin and skin structure infections (ABSSSI).
Read More
UK launch for Cardiome’s skin infections antibiotic
A one- or two-shot antibiotic has been launched in the UK for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
